These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3956050)

  • 1. Salivary antipyrine half-life during injectable progestagen contraception.
    Joshi JV; Gupta KC; Hazari KT; Gokral J; Pohujani S; Satoskar R
    Clin Pharmacokinet; 1986; 11(2):171-5. PubMed ID: 3956050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy.
    Harman AW; Penhall RK; Priestly BG; Frewin DB; Phillips PJ; Clarkson AR
    Aust N Z J Med; 1977 Aug; 7(4):385-90. PubMed ID: 270989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of antipyrine from saliva as a measure of metabolism in man.
    Welch RM; DeAngelis RL; Wingfield M; Farmer TW
    Clin Pharmacol Ther; 1975 Sep; 18(3):249-58. PubMed ID: 1164815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man.
    van Boxtel CJ; Wilson JT; Lindgren S; Sjöqvist F
    Eur J Clin Pharmacol; 1976 Feb; 9(4):327-32. PubMed ID: 971716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of rifampicin on norethisterone pharmacokinetics.
    Back DJ; Breckenridge AM; Crawford F; MacIver M; Orme ML; Park BK; Rowe PH; Smith E
    Eur J Clin Pharmacol; 1979 Apr; 15(3):193-7. PubMed ID: 37091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of antipyrine pharmacokinetics in saliva and plasma using a colourimetric method of antipyrine analysis.
    Harman AE; Priestly BG; Frewin DB
    Clin Exp Pharmacol Physiol; 1977; 4(6):593-6. PubMed ID: 589875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of norethisterone oenanthate in humans.
    Sang GW; Fotherby K; Howard G; Elder M; Bye PG
    Contraception; 1981 Jul; 24(1):15-27. PubMed ID: 7273765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injectable contraception.
    Elder MG
    Clin Obstet Gynaecol; 1984 Dec; 11(3):723-41. PubMed ID: 6239732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of fever on antipyrine metabolism in children.
    Forsyth JS; Moreland TA; Rylance GW
    Br J Clin Pharmacol; 1982 Jun; 13(6):811-5. PubMed ID: 7093111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with injectable progestogen- only contraceptives at University of Ilorin teaching hospital: a five year review.
    Balogun OR; Raji HO
    Niger Postgrad Med J; 2009 Dec; 16(4):260-3. PubMed ID: 20037621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception.
    Kamischke A; Venherm S; Plöger D; von Eckardstein S; Nieschlag E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):303-9. PubMed ID: 11232016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipyrine metabolism during the menstrual cycle.
    Riester EF; Pantuck EJ; Pantuck CB; Passananti GT; Vesell ES; Conney AH
    Clin Pharmacol Ther; 1980 Sep; 28(3):384-91. PubMed ID: 7408398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of salivary concentration data to pharmacokinetic studies with antipyrine.
    Meffin PJ; Williams RL; Blaschke TF; Rowland M
    J Pharm Sci; 1977 Jan; 66(1):135-7. PubMed ID: 833730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
    Enk L; Landgren BM; Lindberg UB; Silfverstolpe G; Crona N
    Horm Metab Res; 1992 Feb; 24(2):85-9. PubMed ID: 1533383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipyrine metabolism in patients with diabetes mellitus.
    Murali KV; Adithan C; Shashindran CH; Gambhir SS; Chandrasekar S
    Clin Exp Pharmacol Physiol; 1983; 10(1):7-13. PubMed ID: 6839551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative performance of a combined injectable contraceptive (50 mg norethisterone enanthate plus 5mg estradiol valerate) and a combined oral contraceptive (0.15 mg levonorgestrel plus 0.03 mg ethinyl estradiol) in adolescents.
    Molina RC; Sandoval JZ; Montero AV; Oyarzún PG; Molina TG; González EA
    J Pediatr Adolesc Gynecol; 2009 Feb; 22(1):25-31. PubMed ID: 19232299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting antipyrine metabolism in West African villagers.
    Fraser HS; Bulpitt CJ; Kahn C; Mould G; Mucklow JC; Dollery CT
    Clin Pharmacol Ther; 1976 Sep; 20(3):369-76. PubMed ID: 954356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.
    Danhof M; van Zuilen A; Boeijinga JK; Breimer DD
    Eur J Clin Pharmacol; 1982; 21(5):433-41. PubMed ID: 7075648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
    Noguchi LM; Richardson BA; Baeten JM; Hillier SL; Balkus JE; Chirenje ZM; Bunge K; Ramjee G; Nair G; Palanee-Phillips T; Selepe P; van der Straten A; Parikh UM; Gomez K; Piper JM; Watts DH; Marrazzo JM;
    Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.